CTOR - MCAP CO - Citius Oncology, Inc.

Citius Oncology, Inc. (CTOR) bases its business on the principles of environmental responsibility, implementing "green chemistry" in its laboratories to protect the environment. The company is currently overcoming a liquidity shortage due to the costs of promoting new drugs, with the key metric standing at 0.11. High physician confidence in targeted leukemia treatments is confirmed by the price action chart shown below, which serves as validation for the market valuation.

Market capitalization is the product of the current share price and the total number of issued securities. This indicator allows for the determination of a business's fair value for a strategic acquisition or the identification of critical overvaluation levels. For Citius Oncology, Inc. (CTOR), a high cash burn rate in the absence of sales turns this metric into a survival indicator. Analyzing the company's total market value helps investors identify advantageous entry points during deep drawdowns.